Abstract
Churg-Strauss syndrome (CSS) is characterized by small-vessel vasculitis, extravascular granulomatous inflammation, and massive eosinophilia in tissues and blood, and is often accompanied by a history of preclinical asthma and/or allergic rhinitis lasting several years before the syndrome develops its full clinical picture. Corticosteroids, often in combination with cytotoxic agents, comprise standard therapy; however, a number of patients appear to be resistant to treatment and there is a need for more effective regimens. B cell depletion may be an effective treatment option for CSS. Here, we describe two patients resistant to conventional therapy who were treated with rituximab and experienced a rapid and substantial decrease in disease activity and asthmatic symptoms and an increase in physical capacity.
References
Calabrese LH, Duna G (2005) Antineutrophil cytoplasmic antibody-associated vasculitis. In: Harris ED Jr et al (eds) Kelly’s textbook of rheumatology, 7th edn. Elsevier Saunders, Philadelphia, pp 1357–1378
Arkfeld DG (2008) The potential utility of B cell-directed biologic therapy in autoimmune diseases. Rheumatol Int 28:205–215
Pepper RJ, Fabre MA, Pavesio C, Gaskin G, Jones RB, Jayne D et al (2008) Rituximab is effective in the treatment of refractory Churg-Strauss syndrome and is associated with diminished T-cell interleukin-5 production. Rheumatology 47:1104–1105
Koukoulaki M, Smith KGC, Jayne DRW (2006) Rituximab in Churg-Strauss syndrome. Ann Rheum Dis 65:557–559
Kaushik VV, Reddy HV, Bucknall RC (2006) Successful use of rituximab in a patient with recalcitrant Churg-Strauss syndrome. Ann Rheum Dis 65:1116–1117
Smith KGC, Jones RB, Burns SM, Jayne DRW (2006) Long-term comparison of rituximab treatment for refractory systemic lupus erythematosus and vasculitis. Arthritis Rheum 54:2970–2982
Isenberg DA (2006) B cell targeted therapies in autoimmune diseases. J Rheumatol 33(Suppl 77):24–28
Hauser T, Mahr A, Metzler C, Coste J, Sommerstein R, Gross WL et al (2008) The leucotriene receptor antagonist montelukast and the risk of Churg-Strauss syndrome: a case crossover study. Thorax 63:677–682
Girszyn N, Amiot N, Lahaxe L, Cuvelier A, Courville P, Marie I (2008) Churg-Strauss syndrome associated with montelukast therapy. Q J Med 101:669–671
Gøransson LG, Brodin C, Øgreid P, Janssen EAM, Romundstad PR, Vatten L et al (2008) Intravenous cyclophosphamide in patients with chronic systemic inflammatory diseases: morbidity and mortality. Scand J Rheumatol 37:130–134
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Dønvik, K.K., Omdal, R. Churg-Strauss syndrome successfully treated with rituximab. Rheumatol Int 31, 89–91 (2011). https://doi.org/10.1007/s00296-009-1146-6
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00296-009-1146-6